Effect of combination therapy with angiotensin receptor blocker and 1,25-dihydroxyvitamin D(3) in type 2 diabetic nephropathy in KK-A(y)/Ta mice. 2011

Ikko Ohara, and Mitsuo Tanimoto, and Tomohito Gohda, and Takahiko Yamazaki, and Shinji Hagiwara, and Maki Murakoshi, and Tatsuya Aoki, and Hitoe Toyoda, and Yuji Ishikawa, and Kazuhiko Funabiki, and Satoshi Horikoshi, and Yasuhiko Tomino
Department of Internal Medicine, Division of Nephrology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan.

BACKGROUND Although angiotensin II type 1 receptor blockers (ARB) have beneficial effects in patients with diabetic nephropathy, they may induce a compensatory increase in renin. Renin exhibits profibrotic actions independent of angiotensin II, which is regulated by extracellular signal-regulated kinase 1 and 2 (ERK1/2). Calcitriol (1,25(OH)(2)D(3)) is a negative inhibitor of the renin-angiotensin system and the present study examined the effects of combination therapy with an ARB and 1,25(OH)(2)D(3) on diabetic nephropathy in KK-A(y)/Ta mice. METHODS KK-A(y)/Ta mice were divided into four groups: ARB group, 1,25(OH)(2)D(3) group, combination group, and control group. The urinary albumin/creatinine ratio (ACR) was measured and the renal expression of renin, p-ERK1/2 and TGF-β1 protein determined. RESULTS The levels of urinary ACR in the combination group were significantly lower than those in the ARB or control group. Renal expression of renin in the ARB group was significantly increased compared with the control group but was significantly decreased in both the 1,25(OH)(2)D(3) and combination group. Renal expression of p-ERK1/2 in the combination group was significantly decreased compared with the control or ARB group. Expression of TGF-β1 protein in the ARB and combination groups, especially the combination group, was significantly decreased compared with those in the control group. CONCLUSIONS These data suggest that the addition of 1,25(OH)(2)D(3) to therapy with ARB further reduced proteinuria by suppressing the compensatory increase in renin expression in type 2 diabetic nephropathy. These effects might relate to suppression of renin, ERK1/2 and TGF-β1 expression which may or may not depend on angiotensin II.

UI MeSH Term Description Entries
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D002117 Calcitriol The physiologically active form of vitamin D. It is formed primarily in the kidney by enzymatic hydroxylation of 25-hydroxycholecalciferol (CALCIFEDIOL). Its production is stimulated by low blood calcium levels and parathyroid hormone. Calcitriol increases intestinal absorption of calcium and phosphorus, and in concert with parathyroid hormone increases bone resorption. 1 alpha,25-Dihydroxycholecalciferol,1 alpha,25-Dihydroxyvitamin D3,1, 25-(OH)2D3,1,25(OH)2D3,1,25-Dihydroxycholecalciferol,1,25-Dihydroxyvitamin D3,1 alpha, 25-dihydroxy-20-epi-Vitamin D3,1,25(OH)2-20epi-D3,1,25-dihydroxy-20-epi-Vitamin D3,20-epi-1alpha,25-dihydroxycholecaliferol,Bocatriol,Calcijex,Calcitriol KyraMed,Calcitriol-Nefro,Decostriol,MC-1288,MC1288,Osteotriol,Renatriol,Rocaltrol,Silkis,Sitriol,Soltriol,Tirocal,1 alpha,25 Dihydroxyvitamin D3,1,25 Dihydroxycholecalciferol,1,25 Dihydroxyvitamin D3,1,25 dihydroxy 20 epi Vitamin D3,Calcitriol Nefro,D3, 1 alpha,25-Dihydroxyvitamin,D3, 1,25-Dihydroxyvitamin,D3, 1,25-dihydroxy-20-epi-Vitamin,KyraMed, Calcitriol,MC 1288
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D003924 Diabetes Mellitus, Type 2 A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY. Diabetes Mellitus, Adult-Onset,Diabetes Mellitus, Ketosis-Resistant,Diabetes Mellitus, Maturity-Onset,Diabetes Mellitus, Non-Insulin-Dependent,Diabetes Mellitus, Slow-Onset,Diabetes Mellitus, Stable,MODY,Maturity-Onset Diabetes Mellitus,NIDDM,Diabetes Mellitus, Non Insulin Dependent,Diabetes Mellitus, Noninsulin Dependent,Diabetes Mellitus, Noninsulin-Dependent,Diabetes Mellitus, Type II,Maturity-Onset Diabetes,Noninsulin-Dependent Diabetes Mellitus,Type 2 Diabetes,Type 2 Diabetes Mellitus,Adult-Onset Diabetes Mellitus,Diabetes Mellitus, Adult Onset,Diabetes Mellitus, Ketosis Resistant,Diabetes Mellitus, Maturity Onset,Diabetes Mellitus, Slow Onset,Diabetes, Maturity-Onset,Diabetes, Type 2,Ketosis-Resistant Diabetes Mellitus,Maturity Onset Diabetes,Maturity Onset Diabetes Mellitus,Non-Insulin-Dependent Diabetes Mellitus,Noninsulin Dependent Diabetes Mellitus,Slow-Onset Diabetes Mellitus,Stable Diabetes Mellitus
D003928 Diabetic Nephropathies KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE. Diabetic Glomerulosclerosis,Glomerulosclerosis, Diabetic,Diabetic Kidney Disease,Diabetic Nephropathy,Intracapillary Glomerulosclerosis,Kimmelstiel-Wilson Disease,Kimmelstiel-Wilson Syndrome,Nodular Glomerulosclerosis,Diabetic Kidney Diseases,Glomerulosclerosis, Nodular,Kidney Disease, Diabetic,Kidney Diseases, Diabetic,Kimmelstiel Wilson Disease,Kimmelstiel Wilson Syndrome,Nephropathies, Diabetic,Nephropathy, Diabetic,Syndrome, Kimmelstiel-Wilson
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D000419 Albuminuria The presence of albumin in the urine, an indicator of KIDNEY DISEASES. Albuminurias
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Ikko Ohara, and Mitsuo Tanimoto, and Tomohito Gohda, and Takahiko Yamazaki, and Shinji Hagiwara, and Maki Murakoshi, and Tatsuya Aoki, and Hitoe Toyoda, and Yuji Ishikawa, and Kazuhiko Funabiki, and Satoshi Horikoshi, and Yasuhiko Tomino
January 2003, Journal of nephrology,
Ikko Ohara, and Mitsuo Tanimoto, and Tomohito Gohda, and Takahiko Yamazaki, and Shinji Hagiwara, and Maki Murakoshi, and Tatsuya Aoki, and Hitoe Toyoda, and Yuji Ishikawa, and Kazuhiko Funabiki, and Satoshi Horikoshi, and Yasuhiko Tomino
November 2004, Metabolism: clinical and experimental,
Ikko Ohara, and Mitsuo Tanimoto, and Tomohito Gohda, and Takahiko Yamazaki, and Shinji Hagiwara, and Maki Murakoshi, and Tatsuya Aoki, and Hitoe Toyoda, and Yuji Ishikawa, and Kazuhiko Funabiki, and Satoshi Horikoshi, and Yasuhiko Tomino
December 2006, International journal of biomedical science : IJBS,
Ikko Ohara, and Mitsuo Tanimoto, and Tomohito Gohda, and Takahiko Yamazaki, and Shinji Hagiwara, and Maki Murakoshi, and Tatsuya Aoki, and Hitoe Toyoda, and Yuji Ishikawa, and Kazuhiko Funabiki, and Satoshi Horikoshi, and Yasuhiko Tomino
February 2007, Metabolism: clinical and experimental,
Ikko Ohara, and Mitsuo Tanimoto, and Tomohito Gohda, and Takahiko Yamazaki, and Shinji Hagiwara, and Maki Murakoshi, and Tatsuya Aoki, and Hitoe Toyoda, and Yuji Ishikawa, and Kazuhiko Funabiki, and Satoshi Horikoshi, and Yasuhiko Tomino
May 2008, Metabolism: clinical and experimental,
Ikko Ohara, and Mitsuo Tanimoto, and Tomohito Gohda, and Takahiko Yamazaki, and Shinji Hagiwara, and Maki Murakoshi, and Tatsuya Aoki, and Hitoe Toyoda, and Yuji Ishikawa, and Kazuhiko Funabiki, and Satoshi Horikoshi, and Yasuhiko Tomino
June 2012, Clinical biochemistry,
Ikko Ohara, and Mitsuo Tanimoto, and Tomohito Gohda, and Takahiko Yamazaki, and Shinji Hagiwara, and Maki Murakoshi, and Tatsuya Aoki, and Hitoe Toyoda, and Yuji Ishikawa, and Kazuhiko Funabiki, and Satoshi Horikoshi, and Yasuhiko Tomino
May 2007, Diabetic medicine : a journal of the British Diabetic Association,
Ikko Ohara, and Mitsuo Tanimoto, and Tomohito Gohda, and Takahiko Yamazaki, and Shinji Hagiwara, and Maki Murakoshi, and Tatsuya Aoki, and Hitoe Toyoda, and Yuji Ishikawa, and Kazuhiko Funabiki, and Satoshi Horikoshi, and Yasuhiko Tomino
February 2009, Clinical journal of the American Society of Nephrology : CJASN,
Ikko Ohara, and Mitsuo Tanimoto, and Tomohito Gohda, and Takahiko Yamazaki, and Shinji Hagiwara, and Maki Murakoshi, and Tatsuya Aoki, and Hitoe Toyoda, and Yuji Ishikawa, and Kazuhiko Funabiki, and Satoshi Horikoshi, and Yasuhiko Tomino
April 2002, Experimental animals,
Ikko Ohara, and Mitsuo Tanimoto, and Tomohito Gohda, and Takahiko Yamazaki, and Shinji Hagiwara, and Maki Murakoshi, and Tatsuya Aoki, and Hitoe Toyoda, and Yuji Ishikawa, and Kazuhiko Funabiki, and Satoshi Horikoshi, and Yasuhiko Tomino
January 2012, Journal of nephrology,
Copied contents to your clipboard!